Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Relevant codes should be used when coding fibromya
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
Pfizer and BioNTech on Monday submitted preliminary clinical data to US health authorities as part of their effort to seek authorization for a third dose of their Covid-19 vaccine for all Americans.
Last week, the United States approved the booster shot of Pfizer-BioNTech and Moderna vaccines for people with weakened immune systems.
“The data we’ve seen to date suggest a third dose of our vaccine elicits antibody levels that significantly exceed those seen after the two-dose primary schedule,” Albert Bourla, Pfizer’s Chairman and Chief Executive Officer, said in a statement.
“A booster vaccine could help reduce infection and disease rates in people who have previously been vaccinated and better control the spread of virus variants during the coming season,” said BioNTech Co-founder Ugur Sahin.
The companies plan to submit the same information to European authorities in the coming weeks.
The move comes despite appeals by the World Health Organization for a moratorium on booster shots to help ease the drastic inequity in dose distribution between rich and poor nations. Israel has also began administering third doses to its citizens.
